Developing new treatments for opioid use disorder
Characterization, optimization, and development of dual mGlu2/3 positive allosteric modulators for opioid use disorder
['FUNDING_R01'] · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · NIH-10544440
This study is looking at new medications that could help people dealing with opioid use disorder and methamphetamine use by exploring how certain brain receptors can help reduce cravings and prevent relapse, with the hope of finding better ways to support recovery.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-10544440 on ClinicalTrials.gov |
What this research studies
This research focuses on creating new medications to help individuals struggling with opioid use disorder (OUD) and those who may also be using methamphetamines. It investigates how certain brain receptors, known as mGlu2 and mGlu3, can be activated to reduce cravings and prevent relapse to drug use. By studying the effects of these receptor activations in animal models, the research aims to identify effective strategies for managing addiction and improving recovery outcomes. The ultimate goal is to provide a novel therapeutic approach that addresses the complex nature of addiction.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with opioid use disorder, particularly those who may also be using methamphetamines.
Not a fit: Patients who are not struggling with opioid use disorder or methamphetamine use may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce the risk of relapse in patients with opioid use disorder.
How similar studies have performed: Previous research has shown promise in using similar approaches to target glutamate receptors for addiction treatment, indicating potential for success in this area.
Where this research is happening
LA JOLLA, UNITED STATES
- SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: COSFORD, NICHOLAS DAVID — SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
- Study coordinator: COSFORD, NICHOLAS DAVID
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.